ArticleBritish journal of haematology2026
A real-world study on different initiation times and treatment durations of letermovir for cytomegalovirus prophylaxis after allogeneic haematopoietic stem cell transplantation.
Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cytomegalovirus (CMV) reactivation is a frequent complication after allogeneic haematopoietic stem cell transplantation (allo-HSCT), but the timing and duration of letermovir prophylaxis in routine practice remain uncertain. We retrospectively reviewed 97 allo-HSCT recipients who received letermovir as primary prophylaxis, focusing on CMV-related outcomes, transplant complications, survival and safety. Letermovir was initiated on day 0 in 31 patients, on day +7 in 44 patients, and on day +14 in 22 patients. The cohort was also stratified by prophylaxis duration, with 51 patients receiving 100-day prophylaxis and 46 patients receiving 200-day prophylaxis. Earlier initiation was associated with a lower 100-day cumulative incidence (CIR) of CMV DNAemia/csCMVi (6.5% vs. 18.2% vs. 36.4%; Gray's test p = 0.008), later first CMV deoxyribonucleic acid (DNA) detection (median 78 vs. 54 vs. 36 days; p = 0.005) and a shorter duration of DNAemia. Compared with the 200-day group, the 100-day group had more late CMV reactivation after discontinuation during follow-up (21.6% vs. 0%; p < 0.001) and numerically lower 1-year overall survival (80.4% [95% confidence interval (CI), 66.6-88.9] vs. 93.5% [95% CI, 81.1-97.8]; log-rank p = 0.103), without more severe chronic graft-versus-host disease or grade ≥3 drug-related adverse events. These real-world findings suggest that both earlier initiation and longer letermovir prophylaxis deserve further evaluation after allo-HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.